MetaVia Inc. (NASDAQ:MTVA) Short Interest Down 55.0% in March

MetaVia Inc. (NASDAQ:MTVA) saw a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 46,186 shares, a decrease of 55.0% from the February 26th total of 102,676 shares. Approximately 2.1% of the company’s stock are short sold. Based on an average daily trading volume, of 118,386 shares, the days-to-cover ratio is currently 0.4 days.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new stake in shares of MetaVia Inc. (NASDAQ:MTVA) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia at the end of the most recent reporting period. 1.37% of the stock is currently owned by institutional investors and hedge funds.

MetaVia Stock Up 1.5%

Shares of MTVA traded up $0.02 during mid-day trading on Thursday, hitting $1.32. The stock had a trading volume of 53,051 shares, compared to its average volume of 265,754. The company has a market cap of $2.90 million, a PE ratio of -0.16 and a beta of 0.33. The company’s fifty day simple moving average is $1.89 and its two-hundred day simple moving average is $6.88. MetaVia has a fifty-two week low of $1.22 and a fifty-two week high of $23.10.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $1.64. Equities analysts expect that MetaVia will post -3.9 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on MTVA. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. HC Wainwright raised their price objective on shares of MetaVia from $12.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, Wall Street Zen lowered shares of MetaVia from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $36.50.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.